Bicycle Therapeutics (BCYC) Income towards Parent Company (2018 - 2026)

Bicycle Therapeutics has reported Income towards Parent Company for 9 years, with the latest figure at -$60.8 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company changed 0.14% year-over-year to -$60.8 million; the trailing twelve-month figure through Mar 2026 stood at -$225.7 million (down 856.59% YoY), and the FY2025 full-year result was -$225.7 million, down 2226.02% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$60.8 million, down from -$26.8 million in the prior quarter.
• The five-year high for Income towards Parent Company was $127.8 million in Q4 2024, with the low at -$79.0 million in Q2 2025.
• Historically, Income towards Parent Company has averaged -$33.8 million across 5 years, with a median of -$39.8 million in 2024.
• Annual changes were most pronounced in 2024 — Income towards Parent Company surged 341.5% — and 2025, when it slumped 129.1%.
• Bicycle Therapeutics' Income towards Parent Company stood at -$32.0 million in 2022, then plunged by 65.19% to -$52.9 million in 2023, then surged by 341.5% to $127.8 million in 2024, then plunged by 121.01% to -$26.8 million in 2025, then slumped by 126.54% to -$60.8 million in 2026.
• The last three Income towards Parent Company figures came in at -$60.8 million (Q1 2026), -$26.8 million (Q4 2025), and -$59.1 million (Q3 2025), per Business Quant data.